Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.
about
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trialsWeekly epirubicin in patients with hormone-resistant prostate cancer.Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer.Prostate cancer clinical trial end points: "RECIST"ing a step backwards.Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?Management of androgen-independent prostate cancer.Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy.Multimodality therapy: bone-targeted radioisotope therapy of prostate cancerPhase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.Basic helix-loop-helix transcription factor DEC2 functions as an anti-apoptotic factor during paclitaxel-induced apoptosis in human prostate cancer cells.Breast cancer and protein biomarkers.Satraplatin for the therapy of castration-resistant prostate cancer.Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer.Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.Combination therapy induces unfolded protein response and cytoskeletal rearrangement leading to mitochondrial apoptosis in prostate cancer.Estramustine plus a taxane for advanced prostate cancer: the new standard therapy?Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer.Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models.Role of chemotherapy in prostate cancer.High-risk localised prostate cancer: multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy.Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study.[How should hormone therapy for castration-resistant prostate cancer be continued?]
P2860
Q24599547-C96C3765-EB29-4C93-B880-0045170A0B52Q33344286-3FD85CA8-958E-4BA9-AF54-DCDB551AAC7AQ33366793-C231EB3F-052E-40C6-9E4D-554938C41E6FQ35751894-560A9CD0-731C-4292-B1C9-91180EE82BA5Q35945262-28606ABB-32E1-47FA-9AD3-7382750943F0Q35996488-BAD6A758-B9BA-4750-8D9A-C50FF874345AQ36088993-DD58B015-B8D6-4246-AFE5-F20935FD74F7Q36740128-095367B3-4290-4E53-AD69-0D16E6BED941Q37193613-6A9262FC-9804-4E62-B4DA-9B76488B1FE9Q37395384-F54C7888-24EF-4D34-9564-A0C5293ADB67Q37426660-45ADBF6F-48B6-4BFB-96AB-BD3191CE516BQ37527713-2C3676B3-DFB5-438C-AB63-C11C5814E438Q37605845-77339D04-586F-4E18-ACB9-5BC6500000B1Q37677557-62EBF237-5A53-47A4-8662-73177427565CQ40070852-BD1FD9CE-3ADF-4752-A0D4-8BCD4948E8ECQ40595610-308F5FC1-C679-4B4B-92C8-CC41EC4049A4Q42382167-CA3193C1-F257-4197-9F4D-E43CE9EA0F75Q44115448-54098D3B-FE90-4E2B-AB6D-595860DD5D45Q46632523-270F0DA9-CED2-4B4D-B457-FCB713FB0A74Q47552772-2F0CAE21-0854-419E-BF95-48EDEA65F9A1Q50074875-C9D0682F-2C73-49FE-A9BA-E19904F45E9CQ53362803-E0309B81-B245-45FF-8240-4C2447503140Q54631608-0E5CCAA2-5D4B-4BD7-BD6E-97E30563F28CQ57135372-667F96C4-4FD2-4DA7-84EE-BE945A3818F1
P2860
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Paclitaxel, estramustine phosp ...... with advanced prostate cancer.
@ast
Paclitaxel, estramustine phosp ...... with advanced prostate cancer.
@en
type
label
Paclitaxel, estramustine phosp ...... with advanced prostate cancer.
@ast
Paclitaxel, estramustine phosp ...... with advanced prostate cancer.
@en
prefLabel
Paclitaxel, estramustine phosp ...... with advanced prostate cancer.
@ast
Paclitaxel, estramustine phosp ...... with advanced prostate cancer.
@en
P2093
P356
P1476
Paclitaxel, estramustine phosp ...... with advanced prostate cancer.
@en
P2093
J McCaffrey
L Schwartz
P356
10.1200/JCO.2001.19.1.44
P407
P577
2001-01-01T00:00:00Z